Health Highlights: Jan. 23, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Insulin Price More Than Doubles in U.S. Some Americans with type 1 diabetes have cut back on their insulin usage as the cost of the lifesaving... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2019 Category: General Medicine Source Type: news

Insulin Price More Than Doubles in U.S.
Title: Insulin Price More Than Doubles in U.S.Category: Health NewsCreated: 1/23/2019 12:00:00 AMLast Editorial Review: 1/23/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - January 23, 2019 Category: Endocrinology Source Type: news

Dance Biopharm Finds Its Rhythm
Dance Biopharm had a lot to celebrate in 2018 and if all goes according to plan the private biotech company will have even more to celebrate this year. The company's flagship product – an insulin product delivered via a smart handheld soft mist inhaler – is currently in two confirmatory phase II studies in type 1 and 2 diabetes patients, and Dance plans to initiate two phase III programs in type 2 diabetes patients in 2019. "2018 was a year where Dance really started to build momentum and come out of stealth mode to move toward a commercially focu...
Source: MDDI - January 22, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Insulin prices more than doubled over 5 years
The surging cost of insulin is causing hardship for some diabetics, who have resorted to cutting back on the drug (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 22, 2019 Category: Consumer Health News Source Type: news

US insulin costs per patient nearly DOUBLED from 2012 to 2016
A person with type 1 diabetes incurred annual insulin costs of $5,705, on average, in 2016. The average cost was roughly half that at $2,864 per patient in 2012, according to a report released today. (Source: the Mail online | Health)
Source: the Mail online | Health - January 22, 2019 Category: Consumer Health News Source Type: news

U.S. insulin costs per patient nearly doubled from 2012 to 2016: study
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Insulin Therapy | Medscape Insulin Therapy | Medscape
Review in-depth clinical information, latest medical news, and guidelines about insulin therapy, including interpretation of glucose and insulin levels, types of insulin (short- or long-acting insulin), insulin intolerance, and insulin delivery systems (daily injections, insulin delivery devices). (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Enhanced method for creating insulin-producing cells
Insulin-producing beta cells, created by a new method from stem cells, can control blood sugar levels in animals, according to research published inStem Cell Reports.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 18, 2019 Category: Endocrinology Source Type: news

Metformin vs. Insulin
Title: Metformin vs. InsulinCategory: MedicationsCreated: 1/18/2019 12:00:00 AMLast Editorial Review: 1/18/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - January 18, 2019 Category: Drugs & Pharmacology Source Type: news

Fidarestat prevents high-fat diet-induced intestinal polyps in ApcMin/+ mice
(Bentham Science Publishers) Recent epidemiological and experimental studies have shown that obesity is a major risk factor for Colorectal Cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2019 Category: Cancer & Oncology Source Type: news

This diabetic federal worker rationed her insulin during the shutdown because debt was scarier than dying
A furloughed federal worker who is diabetic said she resorted to rationing her insulin medication because "the thought of having more debt was scarier than the thought of dying" in her sleep. (Source: CNN.com - Health)
Source: CNN.com - Health - January 17, 2019 Category: Consumer Health News Source Type: news

Food, herbs, and spices that can control blood sugar
(Natural News) Recent estimates show that there are more than 80 million Americans who suffer from insulin resistance. This is a great cause for concern since in just a few years this can condition can progress to cardiovascular disease, high blood pressure, cancer, and diabetes. Insulin is an important metabolic hormone that triggers the uptake... (Source: NaturalNews.com)
Source: NaturalNews.com - January 17, 2019 Category: Consumer Health News Source Type: news

Making the Switch: When Your Patient Can't Afford Insulin Making the Switch: When Your Patient Can't Afford Insulin
For many patients, analogue insulin is simply unaffordable, but using non-analogue insulin can get complicated. Dr Anne Peters shares her tips and tricks for making a safe transition.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Valeritas Announces V-Go & #194; & #174; Received Preferred Status on OptumRx Formularies
Bridgewater, N.J., Jan. 14, 2019 (Globe Newswire) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that V-Go is Preferred on the OptumRx formulary.“We are very excited that V-Go is now Preferred on OptumRx formularies,” said Valeritas CEO, John Timberlake.“V-Go helps patients simplify...This story is related to the following:Pharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - January 17, 2019 Category: Medical Devices Source Type: news

New study identifies specific obesity-related risk factors for kidney cancer
(Spectrum Health) A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors. These factors include multiple measures of obesity, diastolic blood pressure and fasting insulin. In contrast, the study found little evidence for an association with RCC risk for systolic blood pressure, circulating lipids, diabetes or fasting glucose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2019 Category: Cancer & Oncology Source Type: news

Alert dogs help diabetes patients to regulate insulin, finds study
Trained alert dogs can help those living with type 1 diabetes to regulate their insulin, according to new research from a UK university and a charity. (Source: Nursing Times)
Source: Nursing Times - January 16, 2019 Category: Nursing Source Type: news

Medical detection dogs help diabetes patients regulate insulin levels
New research by the University of Bristol in collaboration with Medical Detection Dogs has found that the best trained alert dogs have the potential to vastly improve the quality of life of people living with Type 1 diabetes. (Source: University of Bristol news)
Source: University of Bristol news - January 15, 2019 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Veterinary School; Press Release Source Type: news

Medical detection dogs help diabetes patients regulate insulin levels
(University of Bristol) New research by the University of Bristol in collaboration with Medical Detection Dogs has found that the best trained alert dogs have the potential to vastly improve the quality of life of people living with Type 1 diabetes. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 15, 2019 Category: International Medicine & Public Health Source Type: news

Mom furloughed by shutdown worries about affording insulin
Lynette Gabourel has been a federal employee for 38 years. But as the government shutdown continues, she's stuck worrying about whether to pay her mortgage or buy insulin she needs. Chip Reid reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 15, 2019 Category: Consumer Health News Source Type: news

Valeritas ’ V-Go nabs preferred status on OptumRx formularies
Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device, V-Go, won preferred status on the OptumRx formulary. The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. The V-Go product is worn like a patch and delivers a preset basal rate of insulin over the course of 24 hours. The device can also deliver on-demand bolus dosing at mealtimes. Get the full story at our sister site, Drug Delivery Business News. The post Valeritas’ V-Go nabs preferred status on OptumRx formularies appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 14, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Valeritas Source Type: news

Diabetic, 30, claims she was 'just days from death' at 5st after cutting back on insulin
Becky Rudkin, of Aberdeen, Scotland, battled with eating disorder diabulimia for five years. She was hospitalised for six weeks when her body began to feel numb. (Source: the Mail online | Health)
Source: the Mail online | Health - January 11, 2019 Category: Consumer Health News Source Type: news

Beta Bionics raises $63m for bionic pancreas
Boston-based Beta Bionics said this week that it closed a $63 million Series B round to support the development of its iLet bionic pancreas system for people with Type 1 diabetes. The company’s iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous glucose monitor, the algorithms calculate and dose insulin and/or glucagon as needed. Get the full story at our sister site, Drug Delivery Business News. The post Beta Bionics raises $63m for bionic pancreas appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 10, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Featured Funding Roundup Pharmaceuticals Beta Bionics Source Type: news

Sanofi and Novo Nordisk raise US insulin prices
Cost increase for essential medicine comes as drugmakers face political pressure (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 10, 2019 Category: Pharmaceuticals Source Type: news

New hope for a diabetes cure: Cells in the pancreas could be 'manipulated' into producing insulin  
A study by the universities of Bergen, Norway, and Geneva, Switzerland, found that when beta cells - which make insulin - are wiped out in mice, surrounding cells step in and make the hormone. (Source: the Mail online | Health)
Source: the Mail online | Health - January 9, 2019 Category: Consumer Health News Source Type: news

Dexcom Dominates 2018 with Phenomenal Earnings
Dexcom, which was also a finalist for MDDI’s Medtech Company of the Year, just reported monumental earnings for 2018 despite growing competition in the continuous glucose monitoring market. “We achieved [$1.025] billion in revenue in 2018,” Kevin Sayer, president, CEO and chairman of Dexcom said. “That’s up 43% over what we did in 2017 and that’s over $300 million in growth in a single year for us. I can’t tell you how many things have to go right to make that happen, but a lot of them did.â&#...
Source: MDDI - January 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Study: Even Older Drugs Getting Steep Price Hikes
The cost of a two-pack EpiPen injector has increased from around $100 in 2007 to between $300 and $600 today. The list price for Lantus brand insulin increased by 49 percent in 2014, even though the product has been on the market for more than a decade. (Source: WebMD Health)
Source: WebMD Health - January 8, 2019 Category: Consumer Health News Source Type: news

Medical News Today: Diabetes: Can we teach the body to heal itself?
In a new study in an animal model, researchers investigate the body's potential to replace insulin-producing cells and thus heal itself of diabetes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 8, 2019 Category: Consumer Health News Tags: Diabetes Source Type: news

Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals. Get the full story at our sister site, Drug Delivery Business News. The post Bigfoot Biomedical inks insulin deal with Eli Lilly appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Diabetes Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat Abbott Bigfoot Biomedical Eli Lilly & Co. Source Type: news

What Does Verily Have up Its Sleeve with New Financing Round?
If there’s one thing you can count on, it’s that Verily, Alphabet Inc.’s life sciences division, won’t stay quiet for long. Only a few days into 2019 and Verily, formerly Google’s life sciences arm, is already announcing a $1 billion investment round. The South San Francisco, CA-based company said the hefty round was led by Silver Lake, and proceeds would be used to support growth in key strategic areas, including investments in strategic partnerships, global business development opportunities, and potential acquisitions. Other new in...
Source: MDDI - January 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Business Source Type: news

Mother says son died "because he could not afford his insulin"
The drug industry is starting the New Year by hiking the costs of hundreds of prescription medications despite pressure from President Trump. The price of insulin, a life-saving drug for diabetics, tripled between 2002 and 2013. Since 2008 three of the top makers raised the list price of insulin at least 10 times. Now, the state of Minnesota is taking action by suing three of the world's largest insulin manufacturers. Anna Werner spoke to a mother whose son died after trying to ration his insulin. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 4, 2019 Category: Consumer Health News Source Type: news

Catching Up on News About Catch-Up Sleep
FRIDAY, Jan. 4, 2019 -- Missing out on needed sleep can bring a host of health woes, including diabetes because a lack of sleep affects insulin levels. It also leaves you less alert and less able to focus. And get only four or five hours of sleep... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 4, 2019 Category: General Medicine Source Type: news

Will A No-Booze 'Dry January' Help Your Health?
Dropping alcohol for one month can your lower blood pressure, improve your insulin resistance, and decrease your weight, according to a small study published earlier this year. (Source: WebMD Health)
Source: WebMD Health - January 3, 2019 Category: Consumer Health News Source Type: news

Valeritas ’ V-Go wins preferred status on Humana’s Medicare formularies
Valeritas (NSDQ:VLRX) said today that its V-Go insulin delivery device won preferred status on Humana’s Part D formularies. The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. Worn like a patch, the V-Go product delivers a continuous preset basal rate of insulin over 24 hours and can also provide on-demand bolus dosing at meals. Get the full story at our sister site, Drug Delivery Business News. The post Valeritas’ V-Go wins preferred status on Humana’s Medicare formularies appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 3, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Valeritas Source Type: news

Medical News Today: Diabetes: Drug duo helps body replenish its insulin-producing cells
A new drug combination that spurs adult human beta cells on to regenerate at an unprecedented 5 –8 percent per day is a big step toward a diabetes cure. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 2, 2019 Category: Consumer Health News Tags: Diabetes Source Type: news

The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease
(Bentham Science Publishers) Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 1, 2019 Category: International Medicine & Public Health Source Type: news

What should the Mann Foundation do next?
Brad Perriello, executive editor – Medical at WTWH Media (left), interviews Dr. Robert Greenberg of the Alfred Mann Foundation at DeviceTalks West in Costa Mesa, Calif. [Image by WTWH videographer Graham Smith]Dr. Robert Greenberg, the Mann Foundation’s new executive chairman, has ideas about where to take one of medtech’s top research and development outfits. He explained more at DeviceTalks West in December. The new executive chairman of the Alfred E. Mann Foundation for Scientific Research sees the foundation continuing its mission of developing devices for unmet medical needs. The ...
Source: Mass Device - December 31, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Bioelectronic Medicine Blog Clinical Trials Implants Neuromodulation/Neurostimulation News Well Orthopedics Prosthetics Research & Development Vision Advanced Bionics LLC Alfred E. Mann Foundation Axonics Modulation Technologies Source Type: news

BPA Exposure and Glucose-Stimulated Insulin Response BPA Exposure and Glucose-Stimulated Insulin Response
In what ways might exposure to BPA impact insulin response in humans? This experimental study investigates.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
FRIDAY, Dec. 28, 2018 -- For adults with type 2 diabetes initiating second-line antidiabetic medications (ADM), cardiovascular risk is increased with use of sulfonylureas or basal insulin versus newer ADM classes, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2018 Category: Pharmaceuticals Source Type: news

Scientists study the relationship between obesity and diabetes, discovering that excess weight compromises the immune system, resulting in insulin resistance
(Natural News) German researchers have uncovered a critical link between obesity and diabetes. As reported by MPG.de, a sub-population of immune cells known as natural killer (NK) cells were found to increase the risk of diabetes. The researchers discovered these cells during the course of a different study, one that looked at how the immune... (Source: NaturalNews.com)
Source: NaturalNews.com - December 28, 2018 Category: Consumer Health News Source Type: news

Type 2 Diabetes Could Be a Cause of Erectile Dysfunction Type 2 Diabetes Could Be a Cause of Erectile Dysfunction
Erectile dysfunction may be caused by type 2 diabetes, mediated by insulin resistance, say European researchers, who suggest that lifestyle changes and diabetes drugs may treat the condition.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 26, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

2 Types of Diabetes Meds May Raise Heart Risk
Sulfonylureas were associated with 36 percent higher odds of complications, while basal insulin was associated with nearly twice the risk of heart disease and stroke complications, investigators found. (Source: WebMD Health)
Source: WebMD Health - December 21, 2018 Category: Consumer Health News Source Type: news

Some Second-Line T2D Options Linked With CV Risk
(MedPage Today) -- Observational study reported higher risk with sulfonylureas and basal insulin (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 21, 2018 Category: Cardiology Source Type: news

One in 37 type 2 diabetics taking a commonly prescribed drug will have a heart attack
A study by Northwestern University found that sulfonylureas and basal insulin - which are given to patients if metformin fails - make them more at risk than the newer drug class DPP-4 inhibitors. (Source: the Mail online | Health)
Source: the Mail online | Health - December 21, 2018 Category: Consumer Health News Source Type: news

Insulin, Sulfonylureas Raise Cardiovascular Risk in Diabetes Insulin, Sulfonylureas Raise Cardiovascular Risk in Diabetes
Real-world data also show no cardiovascular harm from newer glucose-lowering agents, but less benefit than was seen in randomized trials of patients with type 2 diabetes and established CVD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

New drug cocktail for diabetes treatment
A new drug cocktail has been developed that elicits the regeneration of insulin-producing beta cells in the pancreas, according to a study published inCell Metabolism.Daily Mail (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 21, 2018 Category: Endocrinology Source Type: news

Beta Bionics Wins Readers & #039; Choice for Medtech Company of the Year
The people have spoken. Beta Bionics has been named medtech company of the year. Nearly 44% of MD+DI readers participating in a special poll voted for the Boston, MA-based company, which is developing an artificial intelligence-powered bionic pancreas, called the iLet, to help manage type 1 diabetes. Beta Bionics pulled ahead of other competitors like Boston Scientific, which was MD+DI Editor’s Choice for medtech company of the year. Each year, MD+DI's editors take a long, hard look at the medical device and diagnostics companies that rose above the ranks over the past 12 months. It can be savvy business ...
Source: MDDI - December 21, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news

Is this a cure for diabetes? Scientists discover insulin-boosting drug 'cocktail'
Researchers from Icahn School of Medicine at Mount Sinai Hospital in New York discovered that when two drugs given in combination can proliferate cells that produce insulin. (Source: the Mail online | Health)
Source: the Mail online | Health - December 20, 2018 Category: Consumer Health News Source Type: news

Scientists Get Closer to Generating Cells Lost to Diabetes
THURSDAY, Dec. 20, 2018 -- People with diabetes often don't have enough insulin-producing beta cells to control their blood sugar, but a combination of two novel drugs may coax the body into making more of these vital cells, an early study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 20, 2018 Category: General Medicine Source Type: news

Diabetes tech execs talk patient-centric design, device development & trust
John Timberlake has been commercializing diabetes drugs and devices for 25 years. Over the course of his career, one theme has always stood out: if you want people to use your product, it has to be made with the end-user in mind. “It’s really [about] understanding the patient first and then designing the technology around the patient,” the Valeritas CEO said this month at DeviceTalks West. The mantra of patient-centric design also rang true with Timberlake’s fellow panelist, Dr. Stephanie Habif of Tandem Diabetes Care – a California-based company that makes the t:slim X2 insulin pump. “T...
Source: Mass Device - December 19, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat DeviceTalks West tandemdiabetes Valeritas Source Type: news

Novartis, China's Gan & Lee push into insulin amid diabetes epidemic
Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China's Gan& Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs. (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news